We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
From May 2019 to May 2024
By Ian Walker
Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) said Monday that it is selling its rabies and tick-borne encephalitis vaccines to Bavarian Nordic AS (BAVA.KO) for up to 955 million euros ($1.07 billion).
Glaxo said the sale of the vaccines--which were bought as part of Novartis AG's (NOVN.EB) vaccine business in 2015--is in line with its plan to simplify the vaccines business.
Glaxo will receive an upfront payment of EUR301 million, milestone payments of EUR495 million and extra payments from inventory sales estimated at EUR159 million.
"This agreement with Bavarian Nordic will enable us to commit greater resources to our key growth assets and to our R&D pipeline, while also ensuring the continued supply of these important and successful vaccines," said Glaxo's President of Global Vaccines Roger Connor.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
October 21, 2019 03:57 ET (07:57 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
